Isofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that 440 patients has been successfully recruited in the global Phase III AGENT study for the treatment for advanced colorectal cancer.